Latest Articles
GSK’s Jemperli Gains Expanded EU Approval for Endometrial Cancer - TipRanks
GSK’s Jemperli Gains Expanded EU Approval for Endometrial Cancer TipRanks
Published: Jan. 21, 2025, 12:20 p.m.
Endometriosis poses substantial burden on Australia’s health system - The Hippocratic Post
Endometriosis poses substantial burden on Australia’s health system The Hippocratic Post
Published: Jan. 21, 2025, 12:05 p.m.
Doctor issues warning about 'number one' early dementia sign as Pauline Quirke diagnosed - Gloucestershire Live
Doctor issues warning about 'number one' early dementia sign as Pauline Quirke diagnosed Gloucestershire Live
Published: Jan. 21, 2025, 10:41 a.m.
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - EIN News
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR EIN News
Published: Jan. 21, 2025, 10:38 a.m.
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? - Medscape
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? Medscape
Published: Jan. 21, 2025, 9:45 a.m.
EC approves GSK’s Jemperli-chemo combo for endometrial cancer - Pharmaceutical Technology
EC approves GSK’s Jemperli-chemo combo for endometrial cancer Pharmaceutical Technology
Published: Jan. 21, 2025, 9:35 a.m.
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer - Medical Dialogues
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer Medical Dialogues
Published: Jan. 21, 2025, 8 a.m.
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer - Indian Pharma Post
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer Indian Pharma Post
Published: Jan. 21, 2025, 4:36 a.m.
Endometriosis and risk of cardiovascular disease: a systematic review and meta-analysis - BMC Public Health
Endometriosis and risk of cardiovascular disease: a systematic review and meta-analysis BMC Public Health
Published: Jan. 21, 2025, 1:41 a.m.
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - ABN Newswire
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR ABN Newswire
Published: Jan. 21, 2025, 12:38 a.m.
Link copied to clipboard!